Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SJ-3366 Sam Jin Pharmaceutical.

Masanori Baba1

  • 1Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Japan. baba@m.kufm.kagoshima-u.ac.jp

Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
PubMed
Summary

SJ-3366 is a novel drug investigated for HIV treatment. It functions as a non-nucleoside reverse transcriptase inhibitor and also blocks HIV-1 entry into cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-activity relationship of neplanocin A analogues for the identification of novel anti-HBV leads.

Organic & biomolecular chemistry·2026
Same author

Potential of fat-soluble vitamins as a platform for antiviral drug development.

Bioorganic & medicinal chemistry letters·2025
Same author

Design, Synthesis, and Anti-SARS-CoV-2 Activity of Amodiaquine Analogs.

Chemical & pharmaceutical bulletin·2025
Same author

Pyrazolo[3,4-<i>d</i>]pyrimidine-based neplanocin analogues identified as potential <i>de novo</i> pharmacophores for dual-target HBV inhibition.

RSC medicinal chemistry·2025
Same author

<i>In Silico</i> Discovery of SARS-CoV-2 Main Protease Inhibitors Using Docking, Molecular Dynamics, and Fragment Molecular Orbital Calculations.

The journal of physical chemistry. B·2025
Same author

Sulfoquinovosyl diacylglycerol, a component of Holy Basil Ocimum tenuiflorum, inhibits the activity of the SARS-CoV-2 main protease and viral replication in vitro.

Journal of natural medicines·2024

Area of Science:

  • Pharmacology
  • Virology
  • Drug Discovery

Background:

  • Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a key class of antiretroviral drugs.
  • Novel therapeutic strategies are needed to combat HIV infection and drug resistance.

Purpose of the Study:

  • To investigate SJ-3366 as a potential treatment for HIV infection.
  • To elucidate the dual mechanism of action of SJ-3366.
  • To assess the patent status and global development of SJ-3366.

Main Methods:

  • Pharmacological evaluation of SJ-3366's activity.
  • Investigation of SJ-3366's interaction with HIV-1 reverse transcriptase.
  • Analysis of SJ-3366's effect on HIV-1 entry post-attachment.

Main Results:

  • SJ-3366 exhibits non-nucleoside reverse transcriptase inhibitor (NNRTI) activity.
  • SJ-3366 interferes with HIV-1 entry at an intermediate stage after virus-cell attachment.
  • Patent applications for SJ-3366 were filed in multiple countries.

Conclusions:

  • SJ-3366 demonstrates a dual mechanism of action against HIV.
  • The compound shows potential as a novel therapeutic agent for HIV infection.
  • Ongoing development and patent filings indicate significant interest in SJ-3366.

Related Experiment Videos